<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Thousand Oaks Biopharmaceuticals Group 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=36939></link><description><![CDATA[Thousand Oaks Biopharmaceuticals Group 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 05:34:59 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2021/01/12_3554238800_20210129134142_9264781753.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Thousand Oaks Biopharmaceuticals Inked a Joint Venture Agreement with Korea’s WSG Group]]></title><link>https://www.newswire.co.kr/newsRead.php?no=917909</link><description><![CDATA[THOUSAND OAKS, Calif./SHANGHAI/BUSAN, South Korea--(Business Wire/Korea Newswire)--January 2021, Thousand Oaks Biopharmaceuticals Group (“Thousand Oaks”) announced that it had signed a Joint Venture agreement with WSG Group in Busan, Korea, to establish a bioprocess solution joint venture (including cell culture media, single-use technology, and related technologies and products) in early 2021. The Joint Venture will speed up ...]]></description><pubDate>Fri, 29 Jan 2021 14:00:00 +0900</pubDate></item><item><title><![CDATA[Thousand Oaks Biopharmaceuticals, 한국 WSG와 합작투자 계약 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=917910</link><description><![CDATA[사우전드 오크스, 캘리포니아/상하이/부산--(Business Wire/뉴스와이어)--2021년 1월 Thousand Oaks Biopharmaceuticals Group(이하 Thousand Oaks)가 부산의 (주)더블유에스지(WSG, 대표 임영환)와 세포배양배지를 포함한 바이오 프로세스 솔루션 합작회사 설립을 위한 합작 투자 계약을 체결했다.  이로써 한국 바이오제약 산업의 발전이 가속화될 것으로 예상되며 이 협력은 세포배양배지의 선도적 공급업체인 JSBiosciences(Thousand Oaks 자회...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2021/01/3554238800_20210129134849_1678370757.jpg]]></url></image><pubDate>Fri, 29 Jan 2021 14:00:00 +0900</pubDate></item></channel></rss>